Morfina Basi (Morphine)

Morphine acts as an agonist at μ‑opioid receptors in the brain and spinal cord. By activating these receptors, it inhibits the release of neurotransmitters that transmit pain signals, producing analgesia and sedation while also influencing respiratory and gastrointestinal function.

The specific dose of Morfina Basi is individualized and set by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, organ function and other clinical factors. No standard dosing regimen is provided in product literature.

Morphine crosses the placenta and is excreted in breast milk, so its use during pregnancy or lactation is generally reserved for situations where the benefit outweighs potential risk. Clinicians should assess each case carefully and consider alternative therapies when possible.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Compared with alternatives such as fentanyl or hydromorphone, morphine has a longer history of use and a well‑characterized safety profile. It is less potent on a milligram‑for‑milligram basis than fentanyl, but its broader therapeutic window and availability in multiple routes make it a common first‑line option for severe pain.

Morfina Basi should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperature fluctuations. Do not freeze the solution, and keep it out of reach of unauthorized personnel.

Morfina Basi is supplied as an injectable solution for intravenous or subcutaneous administration. The medication is drawn into a sterile syringe and given by a qualified healthcare professional, following aseptic technique and appropriate dosing calculations.

The most critical risks include respiratory depression, severe hypotension, profound sedation, and the potential for dependence or abuse. Prompt monitoring of respiratory rate, blood pressure and level of consciousness is essential, especially after dose initiation or escalation.

Morfina Basi is contraindicated in patients with known hypersensitivity to morphine or other opioids, those with significant respiratory insufficiency, acute or severe bronchial asthma, and individuals who have taken monoamine oxidase inhibitors within the past 14 days. Caution is also advised for patients with uncontrolled head injury or increased intracranial pressure.